BUYER AGREEMENT Sample Clauses

BUYER AGREEMENT. Xxxxx agrees to have the puppy examined by a licensed and reputable Veterinarian within 5 business days of taking possession of the puppy to verify the puppy is in good, sound health. If the veterinarian finds the puppy to be at risk due to congenital defect (existing at birth), owner shall notify Breeder and provide a written statement from licensed Veterinarian describing the puppy’s condition and shall return, at Buyer’s expense, the puppy and registration papers to the breeder within three days of the examination. If the puppy is in the same condition mentally and physically as when originally purchased, the Breeder will give a full refund. All Veterinary bills are at the buyer’s expense. This return does not include worms, fleas, mites, ticks, coccidia, giardia, mange or any other parasites as they are common in dogs and puppies. It also does not include ingestion of foreign objects, ingestion of food or chemicals, or physical injury contracted or incurred following Xxxxx’s receipt of puppy. For purposes of this agreement, a reputable veterinarian is one who is duly licensed by the state in which he practices and maintains an active, full-time private practice of which the care of dogs owned as pets is the most significant element of his practice. • The Buyer agrees that this dog will be a household companion. Xxxxx agrees never to tie or chain the puppy out or allow the puppy to roam unsupervised. Shock collars are strongly discouraged for this breed as it can make them very skittish. • In the event of the puppy’s death, the Buyer must notify the Breeder within 36 hours. • The puppy is to receive proper veterinary care and vaccinations for the duration of its life. The next series of puppy vaccines is due in 2-4 weeks after pickup. Please check with your veterinarian for their puppy vaccination schedule. • The Buyer agrees to provide high-quality dog food. The puppy will be fed Puppy Food supplemented with Goat’s Milk while with the Breeder. • The Buyer agrees NEVER to sell/give/trade/transfer ownership of this puppy to any large commercial breeding establishment, any agent, any wholesaler, or any party not included in the original sales agreement. • In the event, at any future time and for any reason, the Buyer cannot keep this puppy, the Buyer should contact the Breeder and the Breeder will make arrangements to assume ownership/care of the puppy/dog. • Xxxxx agrees to release and hold harmless the Breeder for any and all liability, damages, or inju...
Sample 1Sample 2Sample 3See All (11)
AutoNDA by SimpleDocs
BUYER AGREEMENT. Section 3.25
Sample 1Sample 2
BUYER AGREEMENT. If the Buyer and the Supplier enter into the Buyer Agreement, the Buyer and the Supplier will, each at their own expense, do all acts and things necessary or desirable to give effect to the Buyer Agreement.
Sample 1
BUYER AGREEMENT. The developer shall execute the Buyer Agreement in favour of the Allottee in respect of the Premises only upon the Premises being Leased out and all the accounts with the Allottee being settled and all the dues being duly paid to the Developer as per this MOU, including payment of maintenance charges and municipal charges or other outflows etc. It is agreed that both the parties shall be bound by the terms of this MOU and the Buyers Agreement. The provisions of this agreement shall be subject to the Buyers Agreement to
Sample 1
BUYER AGREEMENT. Xxxxx agrees that if at any time, and for any reason, he/she is unable to keep or properly care for the puppy/dog, it shall be returned to the Seller at Buyer’s expenseand to no one else. The Buyer’s understanding and acceptance of this condition is signified here by his/her initials: Date: .
Sample 1
BUYER AGREEMENT. The conclusion of the Reorganization shall not be construed or interpreted as and shall not imply limitation or exclusion of the indemnification obligations assumed by Sellers on behalf of Buyer under this Agreement, which shall remain fully valid, binding and enforceable by Buyer at any time, pursuant to this Agreement.
Sample 1
BUYER AGREEMENT. BUYER insisting to acquire a puppy before 12-15 weeks, should sign an official document acknowledging the risks and releasing the BREEDER of all responsibilities. BUYER has the duty to provide a secure, trustworthy environment in which he raises the dog. BUYER acknowledge that the breed could live 10+ years. BUYER agrees that the Sale Contract will be considered null and void in the event of non- payment of the full amount at the time of delivery and that the deposit payment is Non- refundable. BUYER could proceed to a vet health check within 72 hours after the pickup of the dog/puppy. BUYER acknowledge that all vet bills are the responsibility of the BUYER. BUYER acknowledge that the dog/puppy is sold as Pet Quality and not for Breeding or for Show. Any breeding, even accidental, has to be report to the BREEDER and voids all guarantees. BUYER who can no longer care for the puppy/dog, puppy/dog will be returned to the BREEDER at the costs of the BUYER. BUYER has to notify the reasons and modalities of transport to the BREEDER. The puppy cannot be transferred to a third party without written consent from the BREEDER. BUYER agreed that this contract applies to the original BUYER only and is non-transferable to a second party. BUYER agrees to inform BREEDER of any health issues that might arise in said puppy so BREEDER can work to eliminate them from the breed.
Sample 1
AutoNDA by SimpleDocs

Related to BUYER AGREEMENT

  • The Purchase Agreement This Agreement has been duly authorized, executed and delivered by the Company and the Guarantors.

  • One Agreement This Agreement and any related security or other agreements required by this Agreement, collectively: (a) represent the sum of the understandings and agreements between the Bank and the Borrower concerning this credit; (b) replace any prior oral or written agreements between the Bank and the Borrower concerning this credit; and (c) are intended by the Bank and the Borrower as the final, complete and exclusive statement of the terms agreed to by them. In the event of any conflict between this Agreement and any other agreements required by this Agreement, this Agreement will prevail.

  • Termination Agreement 8.01 Notwithstanding any other provision of this Agreement, WESTERN, at its sole option, may terminate either a Purchase Order or this Agreement at any time by giving fourteen (14) days written notice to CONSULTANT, whether or not a Purchase Order has been issued to CONSULTANT. 8.02 In the event of termination of either a Purchase Order or this Agreement, the payment of monies due CONSULTANT for work performed prior to the effective date of such termination shall be paid within thirty (30) days after receipt of an invoice as provided in this Agreement. Upon payment for such work, CONSULTANT agrees to promptly provide to WESTERN all documents, reports, purchased supplies and the like which are in the possession or control of CONSULTANT and pertain to WESTERN.

  • Letter Agreement The Company shall have entered into the Letter Agreement on terms satisfactory to the Company.

  • Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.

  • Acquisition Agreement Trade Republic acquires Securities outside of Germany if (1) Trade Republic, as a commission agent, executes buy orders in German domestic or foreign Securities outside of Germany or (2) Trade Republic, as a commission agent, executes buy orders in foreign Securities that are traded on the exchange or OTC in Germany but are usually acquired outside of Germany.

  • Stock Purchase Agreement (a) Purchaser understands and agrees that the conversion of the Note into equity securities of the Company may require such Purchaser’s execution of certain agreements (in form reasonably agreeable to a majority in interest of the Purchasers) relating to the purchase and sale of such securities as well as registration, information and voting rights, if any, relating to such equity securities. (b) Purchaser agrees to be bound by the agreements described in Section 2(a).

  • Client Agreement We are not required to enter into a written agreement complying with the Code relating to the services that are to be provided to you.

  • Acquisition Agreements If the Equipment is subject to any Acquisition Agreement, Lessee, as part of this lease, transfers and assigns to Lessor all of its rights, but none of its obligations (except for Lessee's obligation to pay for the Equipment conditioned upon Lessee's acceptance in accordance with Paragraph 6), in and to the Acquisition Agreement, including but not limited to the right to take title to the Equipment. Lessee shall indemnify and hold Lessor harmless in accordance with Paragraph 19 from any liability resulting from any Acquisition Agreement as well as liabilities resulting from any Acquisition Agreement Lessor is required to enter into on behalf of Lessee or with Lessee for purposes of this lease.

  • End User Agreement This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act. This article entitles the maker of a short scientific work funded either wholly or partially by Dutch public funds to make that work publicly available for no consideration following a reasonable period of time after the work was first published, provided that clear reference is made to the source of the first publication of the work. Research outputs of researchers employed by Dutch Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act, are distributed online and free of cost or other barriers in institutional repositories. Research outputs are distributed six months after their first online publication in the original published version and with proper attribution to the source of the original publication. You are permitted to download and use the publication for personal purposes. All rights remain with the author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised under this licence or copyright law is prohibited. If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the University Library know, stating your reasons. In case of a legitimate complaint, the University Library will, as a precaution, make the material inaccessible and/or remove it from the website. Please contact the University Library through email: xxxxxxxxx@xxx.xx.xx. You will be contacted as soon as possible. University Library Radboud University

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!